Date: Sunday, April 30, 2017
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall D1
Introduction: Alemtuzumab (Ale) is a monoclonal antibody targeting CD52+ lympocytes. We sought to determine the impact of Ale immunodepletion, with steroid freedom for low risk patients, on protective immunity.
Methods: An IRB-approved retrospective analysis was performed on 661 patients at the University of Toledo Medical Center who underwent renal transplantation between 3/06 and 11/15.
Results: The total incidence of infection was 236 out of 661 patients (35.7%). The most common infections included E. coli (83), Staph. epidermidis (68), Enterococcus (57), and K. pneumoniae (48).
Infection was greater in female patients (47% vs. 28%; p<0.001) and patients with diabetes mellitus (42.5% vs. 29.7%; p<0.001). No other demographic factors, including race, donor status, age, or recipient pre-sensitization, were significant in patients with infection.
Five-year rejection was significantly greater for patients with infection (34.6%) than those with no infection (24.3%; p=0.043). Other outcomes were not significant.
|Rejection %||Death-Censored Graft Survival %||Patient Survival %|
|Time||Infection||No infection||Infection||No infection||Infection||No infection|
Patients with infection had significantly lower median time rejection-free (831.5 vs. 1131 days; p=0.009), death-censored graft survival (DCGS) time (1298 vs. 1836 days; p=0.002), and patient survival time (1463 vs. 1949 days; p=0.001).
|Table 2: Median Survival Times|
|Death-Censored Graft Survival||1298*||1836|
Conclusion: Incidence of infection was greater in female patients and patients with diabetes mellitus, but no other demographic factors were significant. Infection was only statistically significant for five-year rejection. However, infected patients had significantly shorter rejection-free, DCGS, and patient survival times.
CITATION INFORMATION: Korneffel K, Gehring B, Mitro G, Aboderin O, Makkar S, Han W, Rees M, Ortiz J. Infections and Outcomes in Renal Transplantation Patients Using Alemtuzumab for Induction Immunosuppression: Preliminary Results. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Korneffel K, Gehring B, Mitro G, Aboderin O, Makkar S, Han W, Rees M, Ortiz J. Infections and Outcomes in Renal Transplantation Patients Using Alemtuzumab for Induction Immunosuppression: Preliminary Results. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/infections-and-outcomes-in-renal-transplantation-patients-using-alemtuzumab-for-induction-immunosuppression-preliminary-results/. Accessed November 23, 2020.
« Back to 2017 American Transplant Congress